Cargando…

Is This a 737 Max Moment for Brolucizumab?

Detalles Bibliográficos
Autores principales:	Rosenfeld, Philip J., Browning, David J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263271/ https://www.ncbi.nlm.nih.gov/pubmed/32505363 http://dx.doi.org/10.1016/j.ajo.2020.05.012

Ejemplares similares

Comment on: Is this a 737 Max Moment for Brolucizumab
por: Kayath, Marcia, et al.
Publicado: (2021)

The Boeing 737 MAX: Lessons for Engineering Ethics
por: Herkert, Joseph, et al.
Publicado: (2020)

Brolucizumab and immunogenicity
por: Sharma, Ashish, et al.
Publicado: (2020)

Side Effects of Brolucizumab
por: Motevasseli, Tahmineh, et al.
Publicado: (2021)

Brolucizumab for macular degeneration
Publicado: (2020)

Erratum: Side Effects of Brolucizumab
Publicado: (2022)

The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation
por: Shigemoto, Yumi, et al.
Publicado: (2021)

Brolucizumab—another anti-VEGF or beyond
por: Sharma, Ashish, et al.
Publicado: (2020)

ABT-737 synergizes with Bortezomib to kill melanoma cells
por: Reuland, Steven N., et al.
Publicado: (2011)

Bilaterale Vaskulitis nach intravitrealer Gabe von Brolucizumab
por: Kessler, L. J., et al.
Publicado: (2021)

One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents
por: Coney, Joseph M, et al.
Publicado: (2023)

Comparison of in vitro antileukemic activity of obatoclax and ABT-737
por: Opydo-Chanek, Małgorzata, et al.
Publicado: (2016)

Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration
por: Haug, Sara J., et al.
Publicado: (2020)

CCNP wireless (642-737 IAUWS) quick reference
por: Henry, Jerome
Publicado: (2012)

Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid Streaks
por: Chakraborty, Somnath, et al.
Publicado: (2022)

Gains in the current understanding of managing neovascular AMD with brolucizumab
por: Bodaghi, Bahram, et al.
Publicado: (2023)

Retinal pigment epithelial tear following intravitreal injection of brolucizumab
por: Ashkenazy, Noy, et al.
Publicado: (2021)

Synergistic cytotoxicity of perifosine and ABT‐737 to colon cancer cells
por: Adamová, Barbora, et al.
Publicado: (2022)

Correction to Lancet HIV 2019; 6: e737–49
Publicado: (2020)

Intraokulare Entzündungen bei Brolucizumab-Anwendung: Patientenmanagement – Diagnose – Therapie
por: Holz, F. G., et al.
Publicado: (2021)

Bilateral blindness after uneventful brolucizumab injection for macular degeneration
por: Barchichat, Ilan, et al.
Publicado: (2022)

Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment
por: Mukai, Ryo, et al.
Publicado: (2022)

Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)
por: Van Cleemput, Liesbeth, et al.
Publicado: (2023)

Marked Choroidal Thinning Observed after Intravitreal Brolucizumab Injection
por: Ueta, Yoshiki, et al.
Publicado: (2023)

Brolucizumab for Choroidal Neovascular Membrane with Pigment Epithelial Tear and Subretinal Fluid
por: Bilgic, Alper, et al.
Publicado: (2021)

Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study
por: Bilgic, Alper, et al.
Publicado: (2021)

The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
por: Musiał-Kopiejka, Magdalena, et al.
Publicado: (2022)

Exploiting the Synergy between Carboplatin and ABT-737 in the Treatment of Ovarian Carcinomas
por: Jain, Harsh Vardhan, et al.
Publicado: (2014)

Efficacy, Safety, and Durability of Brolucizumab: An 8-Month Post-Marketing Surveillance Analysis
por: Saba, Nicholas J, et al.
Publicado: (2023)

Brolucizumab: Evaluation of Compassionate Use of a Complex Anti-VEGF Therapy
por: Murray, Julianna E, et al.
Publicado: (2021)

Choroidal Effusion following Intravitreal Brolucizumab Injection: A Case Report
por: Sim, Ha Eun, et al.
Publicado: (2022)

Brolucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies
por: Karasavvidou, Evdoxia-Maria, et al.
Publicado: (2022)

The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice
por: Pearce, Ian, et al.
Publicado: (2022)

Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)
por: Sharma, Ashish, et al.
Publicado: (2020)

Advanced Coats’ disease treated with intravitreal brolucizumab combined with laser photocoagulation
por: Patel, Nimesh A., et al.
Publicado: (2020)

Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
por: Yannuzzi, Nicolas A, et al.
Publicado: (2019)

Contralateral Effect following Intravitreal Brolucizumab Injection in Diabetic Macular Edema
por: Chakraborty, Somnath, et al.
Publicado: (2022)

Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD
por: Khoramnia, Ramin, et al.
Publicado: (2021)

Response of extra-large pigment epithelial detachment to intravitreal brolucizumab injection
por: Chakraborty, Somnath, et al.
Publicado: (2023)

Melatonin Can Modulate the Effect of Navitoclax (ABT-737) in HL-60 Cells
por: Lomovsky, Alexey, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_27cmg298sfsrjlnak4encgirjn